Αποτελέσματα Αναζήτησης
25 Μαΐ 2020 · Abstract. Background: The optimal neoadjuvant treatment for HER2-positive breast cancer is unknown. We wanted to compare the efficacy and safety of the anthracycline regimen EC-TH versus nonanthracycline regimen TCH in neoadjuvant setting for HER2-positive breast cancer.
Introduction. Adjuvant chemotherapy improves outcomes of operable breast cancer. Since the landmark study of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (1), there has been an ongoing effort to identify better regimens to improve survival and decrease toxicity.
31 Ιουλ 2017 · An analysis of the SEER-Medicare database shows that outcomes and healthcare costs for the two chemotherapy regimens are similar, with one difference.
15 Μαρ 2021 · This review found cancer patients pay substantial out-of-pocket costs per month, most of which is spent on cancer medications, followed by caregiver expenses, and transport and travel expenses. Expenditures were highest among pediatric patients and their caregivers.
The costs for chemotherapy (infused and oral therapy combined) in the first 12 months after the diagnosis were $5170, $13,818, $34,425, and $35,686 for stages 0, I/II, III, and IV, respectively. In months 13 to 24 after diagnosis, chemotherapy costs were the largest contributor to the treatment costs in every stage of the disease.
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
Background: Chemotherapy with both anthracyclines and taxanes sequentially or concurrently (ACT) has improved survival in breast cancer. A regimen containing docetaxel and cyclophosphamide (TC) was developed to avoid cardiac side effects, which are of particular concern in older women.
